Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (noted as Mbody AI Ltd. in metadata) covers the period of May 11, 2022. The registrant is a foreign private issuer based in Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of other information rather than a financial statement.
Material Changes
On May 11, 2022, Check-Cap Ltd. announced the initiation of its U.S. Pivotal Trial. This represents a significant operational milestone for the company's clinical development program.
Guidance, Outlook, and Risks
The filing incorporates a press release regarding the U.S. Pivotal Trial by reference. No specific financial guidance, management commentary on future performance, or detailed risk factors are included in the text of this specific Form 6-K.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the U.S. Pivotal Trial protocol and timeline.
- Confirm the company's current ticker symbol and name, as the metadata lists "Mbody AI Ltd." while the filing identifies "Check-Cap Ltd."
- Review the referenced Form S-8 and Form F-3 registration statements for outstanding equity obligations.